Libby's H*O*P*E*

*Helping*Ovarian Cancer Survivors*Persevere Through*Education

Menu

Skip to content
  • Home
  • About
  • Mission
  • Warning Signs & Symptoms
  • Ovarian Cancer Overview
  • Prevention, Early Detection/Screening & Causes
  • Genetics
  • Types of Ovarian Cancer
  • Diagnosis & Staging
  • Treatment Overview
  • Surgery
  • Chemotherapy
  • Radiology & Radiation Therapy
  • Hormonal (Anti-Estrogen) Therapy
  • Biological (Immunotherapy & Vaccine) Therapy
  • Gene Therapy
  • Alternative & Complementary Therapy
  • Clinical Development
  • Clinical Trials
  • Coping
  • Survivorship
  • Ovarian Cancer Resources
  • Contact

Tag Archives: Julie L. Ryan Ph.D. M.P.H.

Ginger Quells Cancer Patients’ Chemotherapy-Related Nausea

Posted on May 16, 2009 by Paul Cacciatore

“People with cancer can reduce post-chemotherapy nausea by 40 percent by using ginger supplements, along with standard anti-vomiting drugs, before undergoing treatment, according to scientists at the University of Rochester Medical Center. …”

Continue reading →

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • Share on Pinterest (Opens in new window) Pinterest
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Tumblr (Opens in new window) Tumblr
  • Share on Reddit (Opens in new window) Reddit
  • Print (Opens in new window) Print
  • Email a link to a friend (Opens in new window) Email
Like Loading...
Posted in Alternative Medicine, Chemotherapy, Coping, Meeting Highlights | Tagged 2009 ASCO Annual Mtg., Anzemet, Community Clinical Oncology Program Research Base, Complementary & Alternative Medicine, ginger, James P. Wilmot Cancer Ctr., Julie L. Ryan Ph.D. M.P.H., National Cancer Institute, Novaban, ovarian cancer, Univ. of Rochester Medical Ctr., Zofran | Leave a comment
"Once you choose hope, anything is possible." -- Christopher Reeve

Categories

RSS Google Ovarian Cancer News

  • Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancer - Nature
  • OSE turns up the heat on ovarian cancer with phase 2 win - Fierce Biotech
  • Ovarian cancer cells use stress hormone signaling to shut down immune system, research reveals - Medical Xpress
  • Short-Term Fasting Enhances Chemotherapy Response in Advanced Ovarian Cancer - MedPage Today
  • Wanting to be child-free, these women got fallopian tube removal. The surgery may also cut ovarian cancer risk - CBC
  • 858 Therapeutics Announces Initial Data from First-in-Human Phase 1/2 Trial of PARG Inhibitor ETX-19477 to be Presented at 2026 ASCO Annual Meeting - BioSpace
  • Ovarian cancer response to chemotherapy may improve with fasting | ASCO 2026 - Managed Healthcare Executive
  • Tedopi Plus Pembrolizumab Extends Survival in Recurrent Ovarian Cancer - The Clinical Trial Vanguard
  • ASCO26: OSE says its vaccine strategy extends PFS in platinum-sensitive ovarian cancer - FirstWord Pharma
  • OSE’s Tedopi-Keytruda combo clears Phase II ovarian cancer hurdle - European Biotechnology Magazine

Top Posts

  • About
    About
  • A Requiem Hallelujah, But Don't Let There Be a Hole in the World Tomorrow
    A Requiem Hallelujah, But Don't Let There Be a Hole in the World Tomorrow
  • Preliminary Findings of a Large British Study Indicate That CA-125 Blood Test & Transvaginal Ultrasound Test Can Detect Early Ovarian Cancer
    Preliminary Findings of a Large British Study Indicate That CA-125 Blood Test & Transvaginal Ultrasound Test Can Detect Early Ovarian Cancer
  • Women's Gynecological Exams:  Another Victim Of The Troubled Economy?
    Women's Gynecological Exams: Another Victim Of The Troubled Economy?
  • Ovarian Cancer Drug AMG 386 Shows Promise With Move To Phase 3 Trials In Australia, Canada & Europe
    Ovarian Cancer Drug AMG 386 Shows Promise With Move To Phase 3 Trials In Australia, Canada & Europe
  • Clinical Trials
    Clinical Trials
  • Endocyte's EC145 Produces Significant Anti-Tumor Activity In Advanced Stage Chemoresistant Ovarian Cancer Patients
    Endocyte's EC145 Produces Significant Anti-Tumor Activity In Advanced Stage Chemoresistant Ovarian Cancer Patients
  • Mission
    Mission
  • Experimental Drug NVP-BEZ235 Slows Ovarian Cancer Growth in Mice; Solid Tumor Clinical Trials Ongoing
    Experimental Drug NVP-BEZ235 Slows Ovarian Cancer Growth in Mice; Solid Tumor Clinical Trials Ongoing
  • 2011 ASCO: EntreMed’s ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients
    2011 ASCO: EntreMed’s ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients

Archives

  • May 2015
  • September 2014
  • August 2014
  • May 2014
  • March 2014
  • August 2013
  • May 2013
  • February 2013
  • January 2013
  • July 2012
  • June 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008

Blog Stats

  • 508,662 Visitors
cancer blog

Enter your email address to subscribe to Libby's H*O*P*E* & receive notifications of new posts by email.

Join 342 other subscribers

 Subscribe in a reader

Click on the orange button above if you want to (i) add Libby's H*O*P*E*(tm) updates to a web-based or other reader, or (ii) embed a Libby's H*O*P*E* (tm) update widget on your desktop, website or blog.

Donate To Ovarian Cancer Research

OCRF is the largest U.S. private funding agency supporting ovarian cancer research. It is a not-for-profit, 501(c)(3) organization. Click on the OCRF logo above to make a donation.

Strategic Partners

Podcasts

Join Us In the Fight Against Ovarian Cancer

RSS New Ovarian Cancer Clinical Trials (Past 14 Days)

  • An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China
  • Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer
  • Sentinel Lymph Node Mapping in Early-Stage Epithelial Ovarian Cancer Surgery
  • Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors
  • OCRA Distress & Unmet Needs
  • Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
  • Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors

RSS New Adult Solid Tumor Clinical Trials (Past 14 Days)

  • Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)
  • A Phase I Study of JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
  • A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer
  • A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
  • Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
  • A Study of IDP-001 in Advanced or Metastatic Solid Tumors
  • Study of GS-2426 in Participants With Advanced Solid Tumors
  • A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)
  • An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China
  • Safety and Activity of HF50 in Patients With Advanced Solid Tumors

RSS Medical Studies

  • Signaling Under Stress: Targeting the Glucocorticoid Receptor in Cancer
  • Ovarian Cancer Outcomes Improve with Fasting During Chemotherapy
  • Circulating Tumor DNA in Tracking Minimal Residual Disease and Recurrence in Ovarian Cancer: A Retrospective Cohort
  • Frequency of optimal and sub-optimal fertility-sparing surgery in young women with ovarian cancer: A single-center observational cohort study
  • Gynecologic cancers in veterans and military service members compared to non-veterans, 2004-2021: A National cancer database study
  • Prognostic Nomogram for Ovarian Cancer Patients on First-Line Maintenance Therapy With PARP Inhibitors: A Retrospective Cohort Study
  • Salt-inducible kinases as druggable targets for immunotherapy of ovarian cancer
  • Preoperative Assessment of Peritoneal Carcinomatosis with [68Ga]Ga-FAPI-46 PET/CT: Agreement with Surgicopathologic PCI and Comparison with MRI and [18F]FDG PET/CT
  • Temporal trends in contraceptive use in British Columbia, Canada between 2001 and 2021: a descriptive analysis
  • Nanomedicines from the patient perspective - 30 years after PEGylated liposomal doxorubicin

Recent Comments

Prometey Bank's avatarPrometey Bank on World Ovarian Cancer Day: Toge…
mikaljhohnashly's avatarmikaljhohnashly on World Ovarian Cancer Day: Toge…
Jan C. Calthrop's avatarJan C. Calthrop on Lab-On-A-Chip: Veridex & M…
Paul Cacciatore's avatarPaul Cacciatore on About
Building a Team for… on About
Kathleen's avatarKathleen on About
Paul Cacciatore's avatarPaul Cacciatore on About
Liz's avatarLiz on About
Paul Cacciatore's avatarPaul Cacciatore on Dana Farber Webchat: The Lates…
Judith Marengere's avatarJudith Marengere on Dana Farber Webchat: The Lates…
Paul Cacciatore's avatarPaul Cacciatore on Dana Farber Webchat: The Lates…
Franca Pichini's avatarFranca Pichini on Dana Farber Webchat: The Lates…
painspeaks's avatarpainspeaks on SU2C Announces the Formation o…
marcy westerling's avatarmarcy westerling on SU2C Announces the Formation o…
anne's avataranne on Dana-Farber Oncologists Differ…

Blogroll

  • Site Meter Site Meter

Cancer Organizations

  • American Cancer Society
  • National Cancer Institute

Everyday Heroes

  • Are You There Cancer? It's Me, Jennie.
  • Bald Heads Are Sexy
  • Butterfly Ballet
  • Cancer Queen
  • Carrie's Journey
  • Chris Bledy
  • Diary of a Cancer Patient
  • I Want To Breathe
  • Janine's News
  • Journey Through Ovarian Cancer
  • Kristi & Brian: Living! With Cancer
  • Laurey Bikes
  • Life Cycle
  • livingly dying
  • Marcheline Bertrand Remembered
  • Meghan's Message
  • Monday Hearts For Madalene
  • My Journey With Teal
  • Nobody Has Ovarian Cancer
  • Out Shine Ovarian Cancer
  • OVACOM
  • Ovarian Cancer News
  • Ovarian Cancer?? pass the wine … now!
  • Scrambled Eggs, Surviving Ovarian Cancer
  • Shannon Miller Lifestyle
  • Still Smiling
  • Strong As Steele
  • Tenaciously Teal
  • The Carcinista
  • What? Me Worry?
  • Will There Be Cows In Heaven?
  • Women of Teal

Inspirational Cancer Advocates

  • Bald Is Beautiful
  • Bicycling For Ovarian Cancer (Craig Broeder)
  • Christine Druther
  • Fran Drescher
  • Imerman Angels
  • Jenn Sommermann: Training For a Cure
  • Jim Valvano
  • Laurey Masterton
  • Maddie Kullen
  • Mothers With Cancer
  • Randy Pausch
  • Sean Swarner
  • Standup2cancer
  • The Rock Band N.E.D.

Ovarian Cancer News Archive

  • Ovarian Cancer News Archive

Ovarian Cancer Organizations

  • National Breast & Ovarian Cancer Connection
  • National Ovarian Cancer Coalition
  • Ovarian Cancer National Alliance
  • Ovarian Cancer Research Fund
  • Ovations For the Cure

U.S. Treatment Centers

  • National Comprehensive Cancer Network Member Institutions
  • NCI-Designated Cancer Centers

Video Archive

  • Ovarian Cancer Video Library
Copyright 2008 - 2016 Paul Cacciatore, Libby's H*O*P*E*(TM), *Helping *Ovarian Cancer Survivors *Persevere Through *Education(TM), all rights reserved.
Paul Cacciatore

Create Your Badge
Site Meter
Blog at WordPress.com.
  • Subscribe Subscribed
    • Libby's H*O*P*E*
    • Join 217 other subscribers
    • Already have a WordPress.com account? Log in now.
    • Libby's H*O*P*E*
    • Subscribe Subscribed
    • Sign up
    • Log in
    • Report this content
    • View site in Reader
    • Manage subscriptions
    • Collapse this bar
%d